We serve Chemical Name:(2H3)Methanol CAS:1849-29-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(2H3)Methanol
CAS.NO:1849-29-2
Synonyms:methanol-d4;Methan-d-ol;Methan-d3-ol;1,1,1-Trideuteromethanol Methyl-d3 alcohol;1,1,1-trideuteromethanol;Methanol-d3;DE305;Perdeuteromethanol;(H)Methanol;EINECS 217-435-9;Methyl-d3 alcohol;MFCD00055877
Molecular Formula:CHD3O
Molecular Weight:35.060
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:48.1±3.0 °C at 760 mmHg
Density:0.8±0.1 g/cm3
Index of Refraction:1.311
PSA:20.23000
Exact Mass:35.045044
LogP:-0.72
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1230 3/PG 2
Packing Group:
Contact us for information like methanol-d4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00055877 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl-d3 alcohol Use and application,DE305 technical grade,usp/ep/jp grade.
Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. (2H3)Methanol manufacturer The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. (2H3)Methanol supplier Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. (2H3)Methanol vendor AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said. (2H3)Methanol factory Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.
